Coeptis Therapeutics Holdings, INC. (COEPW) — SEC Filings

Overview

Coeptis Therapeutics Holdings, INC. (COEPW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Coeptis Therapeutics Holdings, Inc. (COEPW) reported a significant increase in total assets to $14,181,641 as of September 30, 2025, up from $8,908,660 at December 31, 2024, primarily driven by a substantial increase in cash to $4,908,487 from $532,885. The company generated sales of $500,996 for th

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 4 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Coeptis Therapeutics Holdings, INC. is neutral.

Filing Type Overview

Coeptis Therapeutics Holdings, INC. (COEPW) has filed 5 10-Q, 3 10-K/A, 15 8-K, 2 S-1/A, 2 10-K, 1 S-1, 1 SC 13G/A, 1 DEF 14A, 1 SC 13G with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (31)

• Coeptis Assets Surge Amid Widening Losses, Capital Influx — 10-Q · Nov 14, 2025 Risk: high
  Coeptis Therapeutics Holdings, Inc. (COEPW) reported a significant increase in total assets to $14,181,641 as of September 30, 2025, up from $8,908,660 at Decem
• Coeptis Losses Widen to $7.7M Amid Soaring Professional Service Costs — 10-Q · Aug 14, 2025 Risk: high
  Coeptis Therapeutics Holdings, Inc. (COEPW) reported a net loss of $7,755,527 for the six months ended June 30, 2025, an increase from a net loss of $6,036,733
• Coeptis Files 10-K/A, Clarifies Warrant Terms on Nasdaq — 10-K/A · Jun 3, 2025 Risk: low
  Coeptis Therapeutics Holdings, Inc. (COEPW) filed a 10-K/A Amendment No. 1 for the fiscal year ended December 31, 2024, primarily to amend its annual report. Th
• Coeptis Therapeutics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Coeptis Therapeutics Holdings, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly Bull Horn Holdings Corp., is involved
• Coeptis Therapeutics Enters Material Definitive Agreement — 8-K · Apr 28, 2025 Risk: medium
  On April 25, 2025, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement. The company, formerly known as Bull Horn Holdings Corp., is
• Coeptis Therapeutics Files S-1/A Amendment — S-1/A · Apr 4, 2025 Risk: medium
  Coeptis Therapeutics Holdings, Inc. filed an S-1/A amendment on April 4, 2025, detailing its business and financial status. The company, formerly Bull Horn Hold
• Coeptis Therapeutics Holdings, Inc. Files 2024 10-K — 10-K · Mar 28, 2025 Risk: low
  Coeptis Therapeutics Holdings, Inc. filed its 2024 10-K on March 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Bull Hor
• Coeptis Therapeutics Announces Board and Compensation Changes — 8-K · Mar 27, 2025 Risk: medium
  On March 21, 2025, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements.
• Coeptis Therapeutics Files S-1/A Amendment — S-1/A · Feb 7, 2025 Risk: medium
  Coeptis Therapeutics Holdings, Inc. filed an S-1/A amendment on February 7, 2025, detailing its financial performance. For the nine months ended September 30, 2
• Coeptis Therapeutics Files 8-K for Equity Sales — 8-K · Jan 24, 2025 Risk: medium
  On January 17, 2025, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The co
• Coeptis Therapeutics Files 8-K — 8-K · Jan 22, 2025 Risk: low
  On January 21, 2025, Coeptis Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a rout
• Coeptis Therapeutics Files S-1 — S-1 · Jan 10, 2025 Risk: medium
  Coeptis Therapeutics Holdings, Inc. filed an S-1 registration statement on January 10, 2025, detailing its business as a biotechnology company focused on biolog
• Coeptis Therapeutics Files 8-K with Bylaw Amendments — 8-K · Dec 27, 2024 Risk: low
  On December 26, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing amendments to its articles of incorporation and bylaws. The company also
• Coeptis Therapeutics Stockholders to Vote on Share Increase — 8-K · Dec 20, 2024 Risk: medium
  On December 18, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing a special meeting of stockholders. The primary purpose of this meeting w
• Coeptis Therapeutics Raises $1.5M Via Convertible Notes — 8-K · Dec 17, 2024 Risk: medium
  On December 12, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing the closing of a private placement of convertible promissory notes. The
• Coeptis Therapeutics CMO Resigns; Interim Appointed — 8-K · Dec 4, 2024 Risk: medium
  On December 3, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing the resignation of Dr. Robert L. Johnson as Chief Medical Officer, effect
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Coeptis Therapeutics Files Definitive Proxy Statement — DEF 14A · Nov 14, 2024 Risk: low
  Coeptis Therapeutics Holdings, Inc. filed its definitive proxy statement (DEF 14A) on November 14, 2024, for its annual meeting scheduled for December 18, 2024.
• Coeptis Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. filed its Q3 2024 10-Q report on November 13, 2024, covering the period ending September 30, 2024. The company, formerly Bul
• Coeptis Therapeutics Enters Material Definitive Agreement — 8-K · Nov 6, 2024 Risk: medium
  On November 1, 2024, Coeptis Therapeutics Holdings, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibit
• Coeptis Therapeutics Files 8-K: Accountant Change & Financials — 8-K · Sep 30, 2024 Risk: low
  On September 30, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns changes in the registrant's certifying accountant
• Coeptis Therapeutics Faces Delisting Notice — 8-K · Sep 19, 2024 Risk: high
  Coeptis Therapeutics Holdings, Inc. filed an 8-K on September 19, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The compa
• Coeptis Therapeutics Files 2023 10-K/A with Restated Financials — 10-K/A · Aug 16, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. filed an amendment (10-K/A) on August 16, 2024, for its fiscal year ending December 31, 2023. This filing includes restated
• Coeptis Therapeutics Restates Financials Due to Accounting Review — 8-K · Aug 14, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. announced on August 9, 2024, that it will not rely on previously issued financial statements for the fiscal year ended Decem
• Coeptis Therapeutics Faces Nasdaq Delisting Warning — 8-K · Jul 31, 2024 Risk: high
  Coeptis Therapeutics Holdings, Inc. received a notification from Nasdaq on July 30, 2024, indicating it is not in compliance with the minimum bid price requirem
• Coeptis Therapeutics Raises $1.5M in Private Placement — 8-K · Jun 20, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. announced on June 14, 2024, the closing of a private placement of approximately $1.5 million in gross proceeds. The company
• Coeptis Therapeutics Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Coeptis Therapeutics Holdings, Inc. (COEPW) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Coeptis Therapeutics Holdings, Inc. filed a 10-Q for t
• Coeptis Therapeutics Holdings, Inc. Files 2023 10-K — 10-K · Mar 26, 2024 Risk: medium
  Coeptis Therapeutics Holdings, Inc. (COEPW) filed a Annual Report (10-K) with the SEC on March 26, 2024. Coeptis Therapeutics Holdings, Inc. filed its 2023 10-K
• Coeptis Therapeutics Files 10-K/A Amendment to Restate 2022 Financials — 10-K/A · Mar 25, 2024 Risk:
  Coeptis Therapeutics Holdings, Inc. (COEPW) filed a Amended Annual Report (10-K/A) with the SEC on March 25, 2024. Coeptis Therapeutics Holdings, Inc. filed a 1
• SC 13G Filing — SC 13G · Feb 14, 2024
• COEPTIS THERAPEUTICS FACES DELISTING THREAT — 8-K · Feb 1, 2024
  Coeptis Therapeutics Holdings, Inc. (COEP) announced on January 29, 2024, that it received a notice of delisting or failure to satisfy a continued listing rule

Risk Profile

Risk Assessment: Of COEPW's 27 recent filings, 4 were flagged as high-risk, 16 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Coeptis Therapeutics Holdings, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $500,996
• Net Income: -$10,339,146
• EPS: N/A
• Debt-to-Equity: 0.30
• Cash Position: $4,908,487
• Operating Margin: N/A
• Total Assets: $14,181,641
• Total Debt: $3,264,864

Key Executives

• Dr. Robert L. Johnson
• Dr. David M. Weiner

Industry Context

Coeptis Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and effective commercialization strategies. Companies often rely on substantial external funding to advance their pipelines.

Top Tags

biotech (4) · SEC Filing (3) · Biotechnology (3) · 10-Q (3) · financials (3) · sec-filing (3) · amendment (3) · 10-K (3) · Coeptis Therapeutics (3) · Biopharmaceutical (2)

Key Numbers

• Total Assets: $14,181,641 — Increased from $8,908,660 at December 31, 2024, indicating balance sheet growth.
• Cash: $4,908,487 — Significantly increased from $532,885 at December 31, 2024, boosting liquidity.
• Total Sales: $500,996 — Generated for the nine months ended September 30, 2025, compared to zero in the prior year, marking initial revenue generation.
• Net Loss Attributable to Common Stockholders: $10,339,146 — Widened from $7,763,546 for the nine months ended September 30, 2024, indicating increased operational losses.
• Professional Services Expense: $6,363,539 — Increased substantially from $2,476,392 in the prior year, contributing to higher operating costs.
• Net Cash Provided by Financing Activities: $11,290,728 — Significant capital raised for the nine months ended September 30, 2025, supporting operations and growth.
• Total Liabilities: $3,264,864 — Decreased from $5,041,434 at December 31, 2024, improving the company's financial structure.
• Common Shares Outstanding: 5,157,611 — As of September 30, 2025, reflecting share issuances.
• Net Loss: $7,755,527 — for the six months ended June 30, 2025, increased from $6,036,733 in 2024
• Accumulated Deficit: $105,989,201 — as of June 30, 2025, increased from $98,233,673 at December 31, 2024
• Stock Based Compensation Expense: $788,752 — for the six months ended June 30, 2025
• Common Stock Par Value: $0.0001 — Par value per share of COEP common stock
• Warrant Exercise Price: $230.00 — Price per whole warrant for COEPW, exercisable for one-half of one common share
• SEC File Number: 001-39669 — Identifies the company's filing with the SEC
• EIN: 98-1465952 — Employer Identification Number

Related Companies

COEP

Frequently Asked Questions